Prelude Therapeutics presents first interim data from trial of PRT2527

Prelude Therapeutics (PRLD) Incorporated announced the presentation of the first interim clinical data from its ongoing open-label, dose-escalation trial of PRT2527, a potent and highly selective CDK9 inhibitor, as monotherapy and in combination with zanubrutinib in patients with relapsed/refractory lymphoid malignancies. The data were presented at a poster session of the 66th American Society of Hematology Annual Meeting in San Diego, California. Of the 23 efficacy evaluable patients in the monotherapy cohort, complete responses, CRs, were observed in 1 patient and 3 partial responses observed with an overall response rate, ORR, of 17.4%. Of the 13 patients in the combination cohort who were evaluable for efficacy, complete responses were observed in 3 patients and 2 partial responses observed with an overall response rate of 38.5%.